Abstract
The primary objective of the treatment of acute myocardial infarction (AMI), with sudden and unexpected death essentially eliminated by the preventive approach to the ventricular arrhythmias is now the other major complication of AMI : pump failure. Although advances have been made in the treatment of heart failure, it remains the primary cause of in-hospital death from AMI. The extent of ischemic necrosis correlates well with the degree of pump failure and with mortality. Over the last 15 years, intervention trials to reduce infarct size and mortality during the acute phase of AMI have been performed with beta-blockers, calcium antagonists and thrombolytic drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Yusuf S, Peto R, Lewis J, Collins R, Sleigh P (1985). Beta-blockade during and after myocardial infarction:an overview of the randomised trials. Prog Car Dis, 27:335–71
Herlitz J, Elmfeldt D, Holmberg S, Malek I, Nyberg G, Pennert K, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom I, Wedel H, Wilhelmsen L, Wilhelmsson G, Hjalmarson A (1984) Goteborg Metoprolol Trial:Mortality and Causes of Death. Am J Cardiol, 53:9D-14D
The MIAMI trial research group:Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial (with discussants) (1985). Eur Heart J, 6:199–226.
ISIS-1 (First International Study of Infarct Survival) Collaborative Group:Randomised Trial of Intravenous Atenolol Among 16027 Cases of Suspected Acute Myocardial Infarction (1986). Lancet, july 12:57–66
Yusuf S, Sleigh P, Rossi PRF, et al.(1983). Reduction in Infarct Size, Arrhythmias, Chest Pain and Morbidity by Early Intravenous Beta-Blockade in Suspected Acute Myocardial Infarction. Circulation, 67:32–41
Verapamil in Acute Myocardial Infarction:The Danish Study Group on Verapamil in Myocardial Infarction (1984). Eur Heart J, 5:516–528
Pearle DL (1984). Nifedipine in Acute Myocardial Infarction. Am J Cardiol, 54:21E-23E
Gibson RS, Boden WE, Theroux P, Strauss HD, Peatt GM et al.(1986). Diltiazem Reinfarction Study Group:Diltiazem and Reinfarction in Patients with non-Q Wave Myocardial Infarction. Results of a Double-Blind, Randomised Multi-center Trial. N Engl J Med, 315:932–936
GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico): Effectiveness of Intravenous Thrombolytic Treatment in Acute Myocardial Infarction (1986). Lancet, February 22:397–401.
The I.S.A.M. Study Group:A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction: Mortality, Morbidity and Infarct Size at 21 Days (1986). N Engl J Med, 414:1465–1471
TIMI Study Group: The Thrombolysis in Myocardial Infarction. Phase I findings (1985). N Engl J Med, 312:932–936
Schaper W. (1984) Experimental infarcts and the Microcirculation. In “Therapeutic approaches to Myocardial Infarct Size Limitation”. p.79 (New York:Raven Press)
Ferrari R, Ceconi C, Curello S, Bigoli MC, Raddino R, Albertini A, Visioli O, (1984). Reversible and Irreversible Ischemic Damage:Importance of Energy Metabolism. G Ital Cardiol 14/2:867–874
Verstraete M, Bernard R, Bory M et al. (1985). Randomised Trial of Intravenous Recombinant Tissue-Type Plasminogen Activator Versus Intravenous Streptokinase in Acute Myocardial Infarction. Lancet, i:842–847
Meyer J, Merx W, Schmitz H, Erbed R, Dorr T.K., Lambertz H et al. (1982). Percutaneous Transluminal Coronary Angioplasty Immediately After Intracoronary Streptolysis of Transmural Myocardial Infarction. Circulation vol.66: 905–912
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 MTP Press Limited
About this chapter
Cite this chapter
Mauri, F., Roghi, A., Rovelli, F. (1987). Perspectives in the management of acute myocardial infarction. In: Lenzi, S., Descovich, G.C. (eds) Atherosclerosis and Cardiovascular Diseases. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3205-0_15
Download citation
DOI: https://doi.org/10.1007/978-94-009-3205-0_15
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7938-9
Online ISBN: 978-94-009-3205-0
eBook Packages: Springer Book Archive